EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische Studie

Comparison of Sirolimus—Versus Paclitaxel‐Coated Balloons in Coronary Artery Disease: One‐Year Results of Two Real‐World Prospective Registries

Selina Vlieger iD, Jin M Cheng, Filippo Luca Gurgoglione iD, Tay M Heang, Alexander J J Ijsselmuiden, Alfonso Ielasi iD, Eric Boersma, Lee C Yan, Alessandro Sciahbasi iD, Ramesh Singh, George Karavolias, Dario Gattuso und 2 weitere

Catheterization and Cardiovascular Interventions · 2025-07 · 106 (1) · 625-632

DOI: 10.1002/ccd.31587 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Catheterization and Cardiovascular Interventions, online erschienen am 19.05.2025. Verfasst von Selina Vlieger und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Albert Schweitzer Hospital, Dordrecht, the Netherlands. Hauptthemen laut MEDLINE: Angioplasty, Balloon, Coronary, Coated Materials, Biocompatible, Coronary Artery Disease, Coronary Restenosis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Paclitaxel‐(PCB) and sirolimus‐coated balloons (SCB) are used for treatment of in‐stent restenosis (ISR) and de novo (DN) lesions. Studies comparing major adverse cardiac events (MACE) after PCB versus SCB are limited.

Aims

This study aims to contribute to this knowledge gap and enhance the understanding of optimal strategies for treating ISR and DN lesions.

Methods

EASTBOURNE and PEARL are large‐scale, prospective clinical registries, evaluating the performance of drug‐coated balloons. PEARL included patients who underwent percutaneous coronary intervention using Protege PCB and EASTBOURNE included patients treated with MagicTouch SCB in study centers in Europe and Asia. We combined these registries and used logistic regression analysis to assess the association between SCB/PCB and the likelihood of experiencing MACE, a composite of all‐cause mortality, myocardial infarction (MI) and target‐lesion revascularisation (TLR) at 1‐year follow‐up.

Results

Out of 2596 patients, MACE was observed more frequently in ISR lesions ( n = 1292 patients, SCB:17.8% vs. PCB:14.1%, p = 0.12) versus DN lesions ( n = 1304 patients, SCB:6.4% vs. PCB:6.1%, p = 1.00). The adjusted hazards ratio (HR) for MACE was 1.17 (95% CI: 0.59–1.23, p = 0.40). As regards DN lesions, no significant difference was found in MACE (SCB: 6.4% vs. PCB 6.1%, p = 1.00). The adjusted HR for MACE was 1.24 (95% CI: 0.20–2.01, p = 0.13). There were no differences in the individual components of the primary endpoint.

Conclusions

This real‐world comparison demonstrated comparable outcomes between new‐generation PCB and SCB in terms of MACE at 1‐year follow‐up, across different lesion settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angioplasty, Balloon, CoronaryCoated Materials, BiocompatibleCoronary Artery DiseaseCoronary RestenosisPaclitaxelPercutaneous Coronary InterventionSirolimusAgedFemaleHumansMaleMiddle AgedAsiaCardiac CathetersCardiovascular AgentsEuropeMyocardial InfarctionProspective StudiesRegistriesRisk FactorsTime FactorsTreatment Outcome

Stichwörter der Autor:innen

de novo lesionsdrug‐coated balloonin‐stent restenosispaclitaxelpercutaneous coronary interventionsirolimus

Substanzen

Cardiovascular AgentsCoated Materials, BiocompatiblePaclitaxelSirolimus

Autor:innen und Institutionen

  • Department of Cardiology, Albert Schweitzer Hospital, Dordrecht, the Netherlands.
  • Department of Cardiology, ErasmusMC, Rotterdam, the Netherlands.
  • Division of Cardiology, Parma University Hospital, Parma, Italy.
  • DCB Academy, Milan, Italy.
  • Pantai Hospital Ayer Keroh, Melaka, Malaysia.
  • Department of Cardiology, Maastricht University Medical centre, Maastricht, the Netherlands.

ORCID-Profile: Selina Vlieger, Filippo Luca Gurgoglione, Alfonso Ielasi, Alessandro Sciahbasi, Bernardo Cortese

Zitieren

APA

Vlieger, S., Cheng, J. M., Gurgoglione, F. L., Heang, T. M., Ijsselmuiden, A. J. J., Ielasi, A., Boersma, E., Yan, L. C., Sciahbasi, A., Singh, R., Karavolias, G., Gattuso, D., Oemrawsingh, R. M., & Cortese, B. (2025). Comparison of Sirolimus—Versus Paclitaxel‐Coated Balloons in Coronary Artery Disease: One‐Year Results of Two Real‐World Prospective Registries. Catheterization and Cardiovascular Interventions, 106(1), 625-632. https://doi.org/10.1002/ccd.31587

Vancouver

Vlieger S, Cheng JM, Gurgoglione FL, Heang TM, Ijsselmuiden AJJ, Ielasi A, et al. Comparison of Sirolimus—Versus Paclitaxel‐Coated Balloons in Coronary Artery Disease: One‐Year Results of Two Real‐World Prospective Registries. Catheterization and Cardiovascular Interventions. 2025;106(1):625-632. doi:10.1002/ccd.31587

BibTeX
@article{Vlieger2025,
  author = {Vlieger, Selina and Cheng, Jin M and Gurgoglione, Filippo Luca and Heang, Tay M and Ijsselmuiden, Alexander J J and Ielasi, Alfonso and Boersma, Eric and Yan, Lee C and Sciahbasi, Alessandro and Singh, Ramesh and Karavolias, George and Gattuso, Dario and Oemrawsingh, Rohit M and Cortese, Bernardo},
  title = {Comparison of Sirolimus—Versus Paclitaxel‐Coated Balloons in Coronary Artery Disease: One‐Year Results of Two Real‐World Prospective Registries},
  journal = {Catheterization and Cardiovascular Interventions},
  year = {2025},
  volume = {106},
  number = {1},
  pages = {625--632},
  doi = {10.1002/ccd.31587}
}
Kostenlos starten →